This study is designed to look at the effects of naltrexone on weight loss in individuals
treated with antipsychotic medications. Naltrexone is an FDA approved medication for the
management of alcohol dependence and drug dependence, but has not been fully evaluated for
its effect on weight loss in individuals with severe mental illness (i.e. schizophrenia,
schizoaffective disorder, bipolar disorder etc.) The purpose of this study is to find out how
effective two different doses of oral naltrexone is on reducing body weight when compared to
placebo (an inactive substance or "sugar pill").
Phase:
N/A
Details
Lead Sponsor:
Yale University
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)